These Ancient Warriors Ate the Brains of Their Enemies, Study Finds
A new study published in the journal Scientific Reports indicates that ancient warriors ate the brains of their enemies.
The particularly gruesome form of celebration was a common occurrence for the Madelenians, who reportedly consumed the brains of their enemies after battle in order to celebrate the death of their foes. Though it's long been thought that pre-historic European cultures dabbled in cannibalism, the notion wasn't confirmed until recently (via Popular Mechanics) when a team of researchers extracted and analyzed skulls and other human remains from Poland's Maszycka Cave.
According to the Catalan Institute of Human Paleoecology and Social Evolution, more than 68 percent of the 63 bones analyzed contained manipulation 'related to human consumption, such as the removal of muscle bundles, brain, and marrow.' Cranial and mandibular fragments, in particular, 'exhibited modifications related to scalping, defleshing and disarticulation.''The location and frequency of cut marks and intentional fracturing on the skeleton is clear evidence of nutritional exploitation of the bodies, ruling out the hypothesis of funerary treatment without consumption,' explained Francesc Marginedas, head of the Catalan Institute and a researcher there.
The study noted that 'the butchering process took place shortly after death with no period reserved for the bodies to decompose or dry.' The deceased were 'intensively manipulated' to extract all possible fluids and make best use of the cadaver's 'caloric contribution.'
Researchers believe the cannibalistic practice may have begun due to scarce food resources after the Ice Age, but they say it may also have had a ritualistic purpose. 'Cannibalism is a behavior documented at various times in human evolution,' said the study's co-author, Palmira Saladie, a Catalan Institute researcher. 'In prehistoric contexts, it could respond both to survival needs and to ritual practices or even to dynamics of intergroup violence.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
31 minutes ago
- Business Insider
CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company's...
Results in 18 Issued Patents and Allowed Patent Applications Internationally with Nine Total Patent Families SOUTH SAN FRANSCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) ('CERo' or the 'Company') an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that deploy phagocytic (i.e., target-cell eating) mechanisms alongside the array of built-in target cell destroying mechanisms used by T cells, announces two previously announced U.S. patent applications have been granted by the U.S. Patent and Trademark Office (USPTO), and one European patent application has been allowed by the European Patent Office, all of which significantly expand the Company's intellectual property portfolio. The USPTO granted U.S. Patent No. 12,291,557, titled, 'CHIMERIC TIM4 RECEPTORS AND USES THEREOF' on May 6, 2025. The granted claims cover certain design aspects of CER-1236, the Company's lead compound. This patent provides composition of matter protection for a chimeric TIM4 receptor comprising a TIM4 binding domain and canonical T cell signaling domains. Additionally, the European Patent Office has allowed European Patent Application No. 1882166.7 titled, 'CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE' on May 16, 2025. The allowed claims encompass a chimeric engulfment receptor comprising a TIM4 binding domain and TLR2 signaling domain. The allowance of this European patent application expands protection of additional design aspects of CER-1236, which have already been granted in the U.S., Japan, and China. Finally, the USPTO granted U.S. Patent No. 12,303,551, titled, 'CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF,' on May 20, 2025. This patent provides coverage for combination cellular immunotherapy compositions and methods of use for CER-1236. The patent covers combination of a chimeric engulfment receptor CD4 + T cell (CD4 + CER-T cell) with a chimeric antigen receptor CD8 + T cell (CD8 + CAR-T cell) or T cell receptor CD8 + T cell (CD8 + TCR-T cell), and their use to treat cancer. This type of combination therapy could be an exciting avenue to complement the CER-T cell technology with other powerful anti-cancer therapies. CERo's intellectual property portfolio now includes 9 total patent families with protection out to 2042 in the United States. With these additional granted patents and allowed application, CER-1236 and its platform technology is supported by 18 total issued patents and allowed patent application internationally. Chris Ehrlich, CERo Therapeutics CEO, commented, 'We continue to aggressively expand our intellectual property portfolio, as it ensures CERo's success in the market. These patents protect the core innovations of the CER-T technology that differentiate it from other cell therapies and demonstrate the true novelty of our design . We continue to seek a robust range of patents across multiple geographies that cover this technology in general, and CER-1236 in particular. The appreciation of the novelty of the CER-T technology by the patent offices validates the innovation and therapeutic potential of this approach, and we believe that we will continue to grow the portfolio. In the near term, we anticipate updates on our clinical trial progress in AML, and the announcement of initiating human trials to treat ovarian and non-small cell lung cancers.' About CERo Therapeutics Holdings, Inc. CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells ('CER-T'). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor ('CAR-T') cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo has commenced clinical trials for its lead product candidate CER-1236 for hematological malignancies. This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'strive,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo's management. Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and the documents incorporated by reference therein. The risks described in CERo's filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Yahoo
14 hours ago
- Yahoo
Want to live a long and happy life? Try trusting friends, strangers, and government, new study says
Trust in your neighbours, institutions, and society writ large may be a key ingredient to a long and happy life, new research suggests. A study in the journal Psychological Bulletin found that people who are generally more trusting tend to report greater well-being, which measures people's mental health and how content they are with their lives – and is in turn tied to longevity and health. 'Our findings show that trust plays a key role in how happy and satisfied people feel, across all ages, especially so for children, adolescents, and older adults,' Catrin Finkenauer, one of the study's authors and a professor at Utrecht University in the Netherlands, said in a statement. Related Indonesians are flourishing. People in the UK, Germany, and Spain? Not so much, global survey finds For the new study, Finkenauer's team looked at three types of trust: interpersonal trust between people who know each other, trust in institutions like the government and banks, and social trust, or the belief that most people are 'honest, reliable, and benevolent'. They found that people who were more trusting – regardless of the type of trust – tended to report greater well-being. However, the link was stronger among children and teenagers than among adults up through middle age. Trust and well-being also appear to reinforce each other over time, according to the study, a meta-analysis that compiled data from more than 2.5 million people worldwide. Related This small island in Denmark lets stressed students unplug from distractions and study in nature 'Whether it's trust in others, in society, or in institutions, all types matter for well-being,' Finkenauer said. It's not clear whether well-being directly causes health outcomes, but it has been linked to longer lifespans – four to 10 extra years, one analysis from the UK's Ministry of Health found – as well as better mental health and a lower risk of death from heart disease and cancer. Notably, not everyone appears to benefit from trust's boost to well-being. Last year, another study in 38 European countries found that racial and ethnic minorities report lower levels of trust, which can make them more unhappy and dissatisfied with life. Related Where in Europe do teenagers have the best and worst mental health? But that same report found that building trust among minorities helps to boost their well-being, leading researchers to conclude that promoting trust can 'narrow the well-being gap' among people of different backgrounds. 'Trust can't be forced – it has to be earned,' Finkenauer said, adding that families, schools, and governments all bear responsibility for creating supportive, trusting environments. 'When we build trust, we also support mental health and stronger communities,' she said.
Hamilton Spectator
17 hours ago
- Hamilton Spectator
VERSES® 'Digital Brain' Featured in WIRED and Popular Mechanics
VANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) — VERSES AI Inc. (CBOE: VERS; OTCQB: VRSSF) ('VERSES' or the 'Company') a cognitive computing company specializing in next-generation agentic software systems today announced important third-party recognition of its digital-brain architecture, AXIOM, following features in WIRED and Popular Mechanics and public acknowledgement from ARC-AGI benchmark creator François Chollet. WIRED: A 'very original' path to AGI In WIRED 's feature ' A Deep Learning Alternative Can Help AI Agents Gameplay the Real World ,' senior writer Will Knight describes AXIOM as 'a new machine-learning approach that draws inspiration from how the human brain models and learns about the world.' He adds that it 'offers an alternative to the artificial neural networks dominant in modern AI' and highlights its 'impressive efficiency' across multiple video-game environments. François Chollet—Keras inventor, TIME 100 AI honoree, and creator of the ARC-AGI benchmark—told WIRED : 'The general goals of the [VERSES] approach and some of its key features track with what I see as the most important problems to focus on to get to AGI… The work strikes me as very original… We need more people trying out new ideas away from the beaten path of large language models.' Chollet also posted on acknowledging that active inference—as demonstrated by AXIOM, where agents act to reduce uncertainty by aligning their internal world models with reality—is 'badly missing from the deep-learning era' and '100% correct' New Benchmarks For AGI - Gameworlds Chollet's well known benchmark for AGI known as ARC-AGI—which measures progress toward general intelligence—tests AI systems on spatial-reasoning tasks and is used by OpenAI, Google, Anthropic, and others as the industry's gold standard. ARC-AGI 3, the next installment of this benchmark, is expected to deploy 100+ novel game worlds to test a new set of capabilities. We believe that this reflects the AI community's move from static Q&A to interactive environments, where games serve as the medium to force agents to explore, form hypotheses, and spontaneously generalize. AXIOM's Active-Inference engine has already demonstrated these skills: it learns unfamiliar worlds, plans by minimizing uncertainty, and adapts in real time— using its cognitive architecture. On the Gameworld 10K benchmark, AXIOM outperformed Google DeepMind's DreamerV3 by up to 60%, used 99% less compute, and learned 39× faster as validated by Soothsayer Analytics, in June. Popular Mechanics: 'This breakthrough could redefine intelligence forever.' Popular Mechanics also published a feature article titled ' This AI Model Can Mimic Human Thought—And May Even Be Capable of Reading Your Mind ,' calling Genius—VERSES' product suite powered by AXIOM— 'a level up from existing AI' and noting that Genius agents run on watts instead of gigawatts and can operate from a laptop battery rather than the cloud. The article begins: 'AI is learning to think like us, bridging the worlds of biology and technology. This breakthrough could redefine intelligence forever.' 'AXIOM was built for interactive intelligence—exploring, planning, and learning in real time,' said VERSES CEO Gabriel René. 'Active Inference is designed to master new worlds faster, with far less compute and human-like adaptability—bringing us closer to truly human-level AI and, we believe, positioning VERSES as the market leader.' Notes to editors About VERSES VERSES® is a cognitive computing company building next-generation intelligent software systems modeled after the wisdom and genius of Nature. Designed around first principles found in science, physics and biology, our flagship product, Genius,™ is an agentic enterprise intelligence platform designed to generate reliable domain-specific predictions and decisions under uncertainty. Imagine a Smarter World that elevates human potential through technology inspired by Nature. Learn more at , LinkedIn and X . On behalf of the Company Gabriel René, Founder & CEO, VERSES AI Inc. Press Inquiries: press@ Investor Relations Inquiries James Christodoulou, Chief Financial Officer IR@ , +1(212)970-8889
